Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Defects in the functions of RNA binding proteins (RBPs) are at the origin of many diseases; however, targeting RBPs with conventional drugs has proven difficult. PROTACs are a new class of drugs that mediate selective degradation of a target protein through a cell's ubiquitination machinery. PROTACs comprise a moiety that binds the selected protein, conjugated to a ligand of an E3 ligase. Herein, we introduce RNA-PROTACs as a new concept in the targeting of RBPs. These chimeric structures employ small RNA mimics as targeting groups that dock the RNA-binding site of the RBP, whereupon a conjugated E3-recruiting peptide derived from the HIF-1α protein directs the RBP for proteasomal degradation. We performed a proof-of-concept demonstration with the degradation of two RBPs-a stem cell factor LIN28 and a splicing factor RBFOX1-and showed their use in cancer cell lines. The RNA-PROTAC approach opens the way to rapid, selective targeting of RBPs in a rational and general fashion.

Original publication

DOI

10.1002/anie.202012330

Type

Journal article

Journal

Angew Chem Int Ed Engl

Publication Date

08/02/2021

Volume

60

Pages

3163 - 3169

Keywords

Lin28, PROTAC, RNA-binding proteins, oligonucleotides, proteasomal degradation, Base Sequence, Binding Sites, Cell Line, Tumor, Humans, Oligonucleotides, Peptides, Proteolysis, RNA, RNA Splicing Factors, RNA-Binding Proteins, Ubiquitin-Protein Ligases